Expresión del supresor tumoral CD82 en células prostáticas primarias y secundarias en la circulación sanguínea (CPCs) de pacientes con cáncer prostático
CD82 tumor suppressor expression in primary and secondary circulating prostate cells (CPCs) in blood in patients with prostate cancer
a Hematología, Hospital de Carabineros de Chile. Santiago de Chile. Facultad de Medicina, Universidad Mayor. Santiago de Chile. Instituto de Bio-Oncología. Santiago de Chile.
b Fundación Arturo López Pérez. Santiago de Chile. INRAD. Santiago de Chile.
c INRAD. Santiago de Chile.
d División de Urología, Hospital de Carabineros de Chile. Santiago de Chile.
e Residente Urología. Universidad de Santiago de Chile.
Leído
2976
Vecesse ha leído el artículo
726
Total PDF
2250
Total HTML
Información del artículo
ISSN: 20074085Idioma original: Español
Datos actualizados diariamente
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 13 | 9 | 22 |
| 2025 11 | 24 | 25 | 49 |
| 2025 10 | 21 | 13 | 34 |
| 2025 9 | 22 | 12 | 34 |
| 2025 8 | 22 | 31 | 53 |
| 2025 7 | 54 | 7 | 61 |
| 2025 6 | 17 | 6 | 23 |
| 2025 5 | 20 | 4 | 24 |
| 2025 4 | 22 | 4 | 26 |
| 2025 3 | 16 | 4 | 20 |
| 2025 2 | 10 | 3 | 13 |
| 2025 1 | 27 | 4 | 31 |
| 2024 12 | 16 | 8 | 24 |
| 2024 11 | 18 | 6 | 24 |
| 2024 10 | 26 | 6 | 32 |
| 2024 9 | 15 | 6 | 21 |
| 2024 8 | 26 | 4 | 30 |
| 2024 7 | 21 | 3 | 24 |
| 2024 6 | 26 | 7 | 33 |
| 2024 5 | 17 | 2 | 19 |
| 2024 4 | 23 | 6 | 29 |
| 2024 3 | 30 | 3 | 33 |
| 2024 2 | 33 | 6 | 39 |
| 2024 1 | 43 | 13 | 56 |
| 2023 12 | 45 | 13 | 58 |
| 2023 11 | 55 | 12 | 67 |
| 2023 10 | 65 | 29 | 94 |
| 2023 9 | 42 | 13 | 55 |
| 2023 8 | 90 | 9 | 99 |
| 2023 7 | 48 | 2 | 50 |
| 2023 6 | 32 | 3 | 35 |
| 2023 5 | 27 | 3 | 30 |
| 2023 4 | 13 | 3 | 16 |
| 2023 3 | 24 | 2 | 26 |
| 2023 2 | 12 | 1 | 13 |
| 2022 1 | 9 | 2 | 11 |
| 2022 12 | 25 | 6 | 31 |
| 2022 11 | 26 | 11 | 37 |
| 2022 10 | 22 | 14 | 36 |
| 2022 9 | 32 | 7 | 39 |
| 2022 8 | 23 | 9 | 32 |
| 2022 7 | 23 | 8 | 31 |
| 2022 6 | 30 | 10 | 40 |
| 2022 5 | 30 | 9 | 39 |
| 2022 4 | 44 | 10 | 54 |
| 2022 3 | 55 | 11 | 66 |
| 2022 2 | 65 | 4 | 69 |
| 2021 1 | 40 | 11 | 51 |
| 2021 12 | 31 | 4 | 35 |
| 2021 11 | 41 | 11 | 52 |
| 2021 10 | 29 | 10 | 39 |
| 2021 9 | 19 | 6 | 25 |
| 2021 8 | 21 | 5 | 26 |
| 2021 7 | 11 | 2 | 13 |
| 2021 6 | 7 | 8 | 15 |
| 2021 5 | 14 | 7 | 21 |
| 2021 4 | 63 | 17 | 80 |
| 2021 3 | 34 | 6 | 40 |
| 2021 2 | 16 | 6 | 22 |
| 2020 1 | 16 | 7 | 23 |
| 2020 12 | 10 | 2 | 12 |
| 2020 11 | 9 | 3 | 12 |
| 2020 10 | 2 | 3 | 5 |
| 2020 9 | 12 | 9 | 21 |
| 2020 8 | 16 | 13 | 29 |
| 2020 7 | 14 | 4 | 18 |
| 2020 6 | 16 | 8 | 24 |
| 2020 5 | 17 | 6 | 23 |
| 2020 4 | 9 | 4 | 13 |
| 2020 3 | 10 | 3 | 13 |
| 2020 2 | 7 | 4 | 11 |
| 2020 1 | 7 | 2 | 9 |
| 2019 12 | 8 | 4 | 12 |
| 2019 11 | 4 | 7 | 11 |
| 2019 10 | 9 | 4 | 13 |
| 2019 9 | 18 | 1 | 19 |
| 2019 8 | 2 | 7 | 9 |
| 2019 7 | 11 | 10 | 21 |
| 2019 6 | 33 | 17 | 50 |
| 2019 5 | 96 | 24 | 120 |
| 2019 4 | 38 | 10 | 48 |
| 2019 3 | 5 | 0 | 5 |
| 2019 2 | 6 | 7 | 13 |
| 2019 1 | 4 | 1 | 5 |
| 2018 12 | 6 | 3 | 9 |
| 2018 11 | 2 | 0 | 2 |
| 2018 10 | 10 | 15 | 25 |
| 2018 9 | 4 | 6 | 10 |
| 2018 8 | 3 | 1 | 4 |
| 2018 7 | 4 | 1 | 5 |
| 2018 6 | 10 | 1 | 11 |
| 2018 5 | 3 | 0 | 3 |
| 2018 4 | 9 | 2 | 11 |
| 2018 3 | 2 | 0 | 2 |
| 2018 2 | 3 | 0 | 3 |
| 2018 1 | 5 | 0 | 5 |
| 2017 12 | 1 | 0 | 1 |
| 2017 11 | 9 | 1 | 10 |
| 2017 10 | 6 | 0 | 6 |
| 2017 9 | 8 | 3 | 11 |
| 2017 8 | 4 | 0 | 4 |
| 2017 7 | 6 | 3 | 9 |
| 2017 6 | 3 | 1 | 4 |
| 2017 5 | 4 | 0 | 4 |
| 2017 4 | 6 | 2 | 8 |
| 2017 3 | 3 | 43 | 46 |
| 2017 2 | 5 | 2 | 7 |
| 2016 1 | 6 | 0 | 6 |
| 2016 12 | 6 | 2 | 8 |
| 2016 11 | 3 | 2 | 5 |
| 2016 10 | 7 | 0 | 7 |
| 2016 9 | 4 | 1 | 5 |
| 2016 8 | 2 | 0 | 2 |
| 2016 7 | 2 | 1 | 3 |
Mostrar todo